



(11) **EP 2 315 780 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
C07K 16/28 ^(2006.01) **A61K 39/395** ^(2006.01)
A61P 37/06 ^(2006.01) **A61P 19/02** ^(2006.01)

(48) Corrigendum issued on:
23.09.2015 Bulletin 2015/39

(86) International application number:
PCT/EP2009/059030

(45) Date of publication and mention
of the grant of the patent:
19.08.2015 Bulletin 2015/34

(87) International publication number:
WO 2010/007082 (21.01.2010 Gazette 2010/03)

(21) Application number: **09797499.2**

(22) Date of filing: **15.07.2009**

(54) **COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES**

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERWENDUNG FÜR THERAPEUTISCHE
ANTIKÖRPER

COMPOSITIONS ET PROCÉDÉS À UTILISER POUR DES ANTICORPS THÉRAPEUTIQUES

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL
PT RO SE SI SK SM TR**
Designated Extension States:
AL BA RS

• **WOISETSCHLAEGER, Maximilian**
2380 Perchtoldsdorf (AT)

(30) Priority: **17.07.2008 EP 08160671**
15.05.2009 EP 09160326

(56) References cited:
WO-A-2006/073941 WO-A-2008/008482

(43) Date of publication of application:
04.05.2011 Bulletin 2011/18

• **LEE CHINGWEI V ET AL: "Synthetic anti-BR3
antibodies that mimic BAFF binding and target
both human and murine B cells." BLOOD 1 NOV
2006, vol. 108, no. 9, 1 November 2006
(2006-11-01), pages 3103-3111, XP002509032
ISSN: 0006-4971**

(73) Proprietor: **Novartis AG**
4056 Basel (CH)

• **LIN WEI YU ET AL: "Anti-BR3 antibodies: a new
class of B-cell immunotherapy combining
cellular depletion and survival blockade."
BLOOD 1 DEC 2007, vol. 110, no. 12, 1 December
2007 (2007-12-01), pages 3959-3967,
XP002509033 ISSN: 0006-4971**

(72) Inventors:
• **HEUSSER, Christoph**
4002 Basel (CH)
• **NEUGEBAUER, Julia**
81677 München (DE)
• **SCHAADT, Eveline**
81543 München (DE)
• **URLINGER, Stefanie**
80689 München (DE)

• **EISENBERG R: "Combination biologics: 1 Stone,
2 birds" BLOOD 20071201 US, vol. 110, no. 12, 1
December 2007 (2007-12-01), page 3817,
XP002509034**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 315 780 B8

- NG LAI GUAN ET AL: "B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 JUL 2004, vol. 173, no. 2, 15 July 2004 (2004-07-15) , pages 807-817, XP002509036 ISSN: 0022-1767
- ZHANG XIN ET AL: "BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors." INTERNATIONAL IMMUNOLOGY JUN 2005, vol. 17, no. 6, June 2005 (2005-06), pages 779-788, XP002509035 ISSN: 0953-8178